Back to search results

Dexmedetomidine for Electrical Storm

This study is looking at whether a medicine called dexmedetomidine can help patients experiencing "electrical storm." Electrical storm is a serious condition where your heart has many abnormal rhythms (ventricular tachycardia, ventricular fibrillation) in a short time. Researchers want to see if giving dexmedetomidine early on, compared to a placebo (normal saline), can reduce the risk of death in the hospital or needing more treatment for these heart rhythms. You could be eligible if you are over 18, admitted to an intensive care unit with electrical storm, and do not have certain severe heart conditions or recent cardiac arrest. The study aims to enroll 192 participants, but its current status is unclear.

Study design
This is a multi-center, double-blinded, placebo-controlled, randomized trial. It plans to enroll 192 participants.
What's involved
Patients will receive either dexmedetomidine or normal saline for 48 to 72 hours as part of their initial treatment in an intensive care unit.
Compensation
Not stated in the trial record.
Follow-up
The main outcomes are measured during the hospital stay, which averages about two weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06281977

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Recruiting
PHASE3Ages 18+InterventionalTreatment
Ottawa Heart Institute Research Corporation
~192 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:DexmedetomidineNormal saline

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.
Measured over Duration of index hospitalization - an average of 2 weeks

Conditions

Ventricular Tachycardia
Ventricular Arrhythmias
Ventricular Fibrillation
Recurrent Ventricular Tachycardia

Explore related trials

Electrical StormVentricular Arrhythmia

NCT06281977

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Not yet recruiting

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canadastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

F. Daniel Ramirez, MD MSc
[email protected]
613-696-7402
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors
SCAI class D or E cardiogenic shock
Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.
ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.
Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.
Pregnancy
Known dexmedetomidine allergy or intolerance
Inability to obtain consent from patient or substitute decision maker.
Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization

What this trial measures

  • The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.Duration of index hospitalization - an average of 2 weeks

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo